dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: OX40

Ligand: vonlerolizumab (Antibody)
Interaction type: Antibody
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
Published in: Journal for Immunotherapy of Cancer

Ligand: rocatinlimab (Antibody)
Interaction type: Antibody
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: OX-40 ligand (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: compound 1 [PMID: 24930776] (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 5.920000076293945 pIC50
Reference (Journal): Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction.
Published in: Br J Pharmacol
Target family: Tumour necrosis factor (TNF) receptor family (type: catalytic_receptor)
Target: nerve growth factor receptor

Ligand: NGF (Peptide)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: EMA (2017), FDA (2018)
Primary target: no
Median affinity: 6 pIC50
Reference (Journal): Chemical modulators working at pharmacological interface of target proteins.
Published in: Bioorg Med Chem

Ligand: neurotrophin-4 (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: neurotrophin-3 (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: LM11A-31 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death.
Published in: J Neurosci

Ligand: BDNF (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: Two-pore domain potassium channels  (K<sub>2P</sub>) (type: vgic)
Target: K<sub>2P</sub>18.1

Ligand: quinine (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (2005, as quinine sulfate, previous history unspecified)
Median affinity:  -
Target family: Two-pore domain potassium channels  (K<sub>2P</sub>) (type: vgic)
Target: K<sub>2P</sub>2.1

Ligand: arachidonic acid (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 5 pEC50
Reference (Journal): A mammalian two pore domain mechano-gated S-like K+ channel.
Published in: EMBO J
Target family: Two-pore domain potassium channels  (K<sub>2P</sub>) (type: vgic)
Target: K<sub>2P</sub>17.1

Ligand: chloroform (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Genomic and functional characteristics of novel human pancreatic 2P domain K(+) channels.
Published in: Biochem Biophys Res Commun

Ligand: NO (Inorganic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1999), EMA (2001)
Median affinity:  -
Reference (Journal): Pancreatic two P domain K+ channels TALK-1 and TALK-2 are activated by nitric oxide and reactive oxygen species.
Published in: J Physiol (Lond.)
Target family: Two-pore domain potassium channels  (K<sub>2P</sub>) (type: vgic)
Target: K<sub>2P</sub>18.1

Ligand: arachidonic acid (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A novel two-pore domain K+ channel, TRESK, is localized in the spinal cord.
Published in: J Biol Chem

Ligand: Ba2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: quinidine (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1950)
Median affinity:  -
Target family: Two-pore domain potassium channels  (K<sub>2P</sub>) (type: vgic)
Target: K<sub>2P</sub>9.1

Ligand: ruthenium red (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 6.16 pIC50

Ligand: ruthenium red (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: R-(+)-methanandamide (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): TASK-3, a novel tandem pore domain acid-sensitive K+ channel. An extracellular histiding as pH sensor.
Published in: J Biol Chem

Ligand: halothane (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1958)
Primary target: yes
Median affinity:  -
Reference (Journal): Modulation of TASK-1 (Kcnk3) and TASK-3 (Kcnk9) potassium channels: volatile anesthetics and neurotransmitters share a molecular site of action.
Published in: J Biol Chem

Ligand: anandamide (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): TASK-3, a novel tandem pore domain acid-sensitive K+ channel. An extracellular histiding as pH sensor.
Published in: J Biol Chem
Target family: Two-pore domain potassium channels  (K<sub>2P</sub>) (type: vgic)
Target: K<sub>2P</sub>6.1

Ligand: quinidine (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1950)
Median affinity:  pIC50
Reference (Journal): TWIK-2, an inactivating 2P domain K+ channel.
Published in: J Biol Chem

Ligand: Ba2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): TWIK-2, an inactivating 2P domain K+ channel.
Published in: J Biol Chem
Target family: Two-pore domain potassium channels  (K<sub>2P</sub>) (type: vgic)
Target: K<sub>2P</sub>5.1

Ligand: quinidine (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1950)
Median affinity:  -
Reference (Journal): Single-channel properties and pH sensitivity of two-pore domain K+ channels of the TALK family.
Published in: Biochem Biophys Res Commun

Ligand: halothane (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1958)
Median affinity: 3.7 pIC50
Reference (Journal): Volatile anesthetics activate the human tandem pore domain baseline K+ channel KCNK5.
Published in: Anesthesiology

Ligand: clofilium (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 4.6 pIC50
Reference (Journal): Modulation of the two-pore domain acid-sensitive K+ channel TASK-2 (KCNK5) by changes in cell volume.
Published in: J Biol Chem
Target family: Two-pore domain potassium channels  (K<sub>2P</sub>) (type: vgic)
Target: K<sub>2P</sub>4.1

Ligand: riluzole (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1995), EMA (1996)
Primary target: no
Median affinity:  -
Reference (Journal): The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK.
Published in: Mol Pharmacol

Ligand: riluzole (Synthetic organic)
Interaction type: Activator
Action: Positive
Ligand approved: yes
Approval source: FDA (1995), EMA (1996)
Primary target: no
Median affinity:  -
Reference (Journal): The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK.
Published in: Mol Pharmacol

Ligand: Ba2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Arachidonic acid activation of a new family of K+ channels in cultured rat neuronal cells.
Published in: J Physiol (Lond.)

Ligand: arachidonic acid (Metabolite)
Interaction type: Activator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Arachidonic acid activation of a new family of K+ channels in cultured rat neuronal cells.
Published in: J Physiol (Lond.)

Ligand: arachidonic acid (Metabolite)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A neuronal two P domain K+ channel stimulated by arachidonic acid and polyunsaturated fatty acids.
Published in: EMBO J
Target family: Two-pore domain potassium channels  (K<sub>2P</sub>) (type: vgic)
Target: K<sub>2P</sub>2.1

Ligand: riluzole (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1995), EMA (1996)
Primary target: no
Median affinity:  -

Ligand: norfluoxetine (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5.050000190734863 pIC50
Reference (Journal): Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine.
Published in: Br J Pharmacol

Ligand: isoflurane (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1979)
Primary target: no
Median affinity:  -
Reference (Journal): Inhalational anesthetics activate two-pore-domain background K+ channels.
Published in: Nat Neurosci

Ligand: halothane (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1958)
Primary target: no
Median affinity:  -
Reference (Journal): Inhalational anesthetics activate two-pore-domain background K+ channels.
Published in: Nat Neurosci

Ligand: GI‐530159 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.119999885559082 pEC50
Reference (Journal): GI-530159, a novel, selective, mechanosensitive two-pore-domain potassium (K<sub>2P</sub> ) channel opener, reduces rat dorsal root ganglion neuron excitability.
Published in: Br J Pharmacol

Ligand: GI‐530159 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.050000190734863 pEC50
Reference (Journal): GI-530159, a novel, selective, mechanosensitive two-pore-domain potassium (K<sub>2P</sub> ) channel opener, reduces rat dorsal root ganglion neuron excitability.
Published in: Br J Pharmacol

Ligand: chloroform (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Inhalational anesthetics activate two-pore-domain background K+ channels.
Published in: Nat Neurosci

Ligand: BL-1249 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5.260000228881836 pEC50
Reference (Journal): Protein and Chemical Determinants of BL-1249 Action and Selectivity for K<sub>2P</sub> Channels.
Published in: ACS Chem Neurosci
Target family: Two-pore domain potassium channels  (K<sub>2P</sub>) (type: vgic)
Target: K<sub>2P</sub>10.1

Ligand: arachidonic acid (Metabolite)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Human TREK2, a 2P domain mechano-sensitive K+ channel with multiple regulations by polyunsaturated fatty acids, lysophospholipids, and Gs, Gi, and Gq protein-coupled receptors.
Published in: J Biol Chem

Ligand: BL-1249 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5.099999904632568 pEC50
Reference (Journal): Protein and Chemical Determinants of BL-1249 Action and Selectivity for K<sub>2P</sub> Channels.
Published in: ACS Chem Neurosci

Ligand: docosahexaenoic acid (Metabolite)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Human TREK2, a 2P domain mechano-sensitive K+ channel with multiple regulations by polyunsaturated fatty acids, lysophospholipids, and Gs, Gi, and Gq protein-coupled receptors.
Published in: J Biol Chem

Ligand: GI‐530159 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): GI-530159, a novel, selective, mechanosensitive two-pore-domain potassium (K<sub>2P</sub> ) channel opener, reduces rat dorsal root ganglion neuron excitability.
Published in: Br J Pharmacol

Ligand: halothane (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1958)
Primary target: yes
Median affinity:  -
Reference (Journal): Human TREK2, a 2P domain mechano-sensitive K+ channel with multiple regulations by polyunsaturated fatty acids, lysophospholipids, and Gs, Gi, and Gq protein-coupled receptors.
Published in: J Biol Chem

Ligand: linoleic acid (Metabolite)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Human TREK2, a 2P domain mechano-sensitive K+ channel with multiple regulations by polyunsaturated fatty acids, lysophospholipids, and Gs, Gi, and Gq protein-coupled receptors.
Published in: J Biol Chem

Ligand: lysophosphatidylcholine (Metabolite)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Human TREK2, a 2P domain mechano-sensitive K+ channel with multiple regulations by polyunsaturated fatty acids, lysophospholipids, and Gs, Gi, and Gq protein-coupled receptors.
Published in: J Biol Chem

Ligand: quinidine (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity:  -
Reference (Journal): Characterization of four types of background potassium channels in rat cerebellar granule neurons.
Published in: J Physiol (Lond.)
Target family: Two-pore domain potassium channels  (K<sub>2P</sub>) (type: vgic)
Target: K<sub>2P</sub>12.1

Ligand: halothane (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Approval source: FDA (1958)
Primary target: no
Median affinity:  -
Reference (Journal): Tandem pore domain halothane-inhibited K+ channel subunits THIK1 and THIK2 assemble and form active channels.
Published in: J Biol Chem
Target family: Two-pore domain potassium channels  (K<sub>2P</sub>) (type: vgic)
Target: K<sub>2P</sub>13.1

Ligand: arachidonic acid (Metabolite)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Tandem pore domain halothane-inhibited K+ channel subunits THIK1 and THIK2 assemble and form active channels.
Published in: J Biol Chem

Ligand: Ba2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: CVN293 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.309999942779541 pIC50
Reference (Journal): Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment.
Published in: ACS Med Chem Lett

Ligand: CVN293 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.550000190734863 pIC50
Reference (Journal): Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment.
Published in: ACS Med Chem Lett

Ligand: halothane (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Approval source: FDA (1958)
Primary target: no
Median affinity:  -
Reference (Journal): Tandem pore domain halothane-inhibited K+ channel subunits THIK1 and THIK2 assemble and form active channels.
Published in: J Biol Chem
Target family: Two-pore domain potassium channels  (K<sub>2P</sub>) (type: vgic)
Target: K<sub>2P</sub>16.1

Ligand: Ba2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Genomic and functional characteristics of novel human pancreatic 2P domain K(+) channels.
Published in: Biochem Biophys Res Commun

Ligand: chloroform (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Genomic and functional characteristics of novel human pancreatic 2P domain K(+) channels.
Published in: Biochem Biophys Res Commun

Ligand: isoflurane (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1979)
Median affinity:  -
Reference (Journal): Genomic and functional characteristics of novel human pancreatic 2P domain K(+) channels.
Published in: Biochem Biophys Res Commun

Ligand: NO (Inorganic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1999), EMA (2001)
Median affinity:  -
Reference (Journal): Genomic and functional characteristics of novel human pancreatic 2P domain K(+) channels.
Published in: Biochem Biophys Res Commun

Ligand: quinidine (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1950)
Median affinity:  -
Reference (Journal): Genomic and functional characteristics of novel human pancreatic 2P domain K(+) channels.
Published in: Biochem Biophys Res Commun
Target family: Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family (type: catalytic_receptor)
Target: fms related receptor tyrosine kinase 3

Ligand: midostaurin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA & EMA (2017)
Primary target: yes
Median affinity: 6.28000020980835 pIC50
Reference (Journal): Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
Published in: Cancer Cell
Target family: Type II PIP kinases (1-phosphatidylinositol-5-phosphate 4-kinase family) (type: enzyme)
Target: phosphatidylinositol-5-phosphate 4-kinase type 2 alpha

Ligand: BAY-091 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.890000343322754 pIC50
Reference (Journal): Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A.
Published in: J Med Chem

Ligand: BAY-297 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.890000343322754 pIC50
Reference (Journal): Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A.
Published in: J Med Chem
Target family: Type II receptor serine/threonine kinases (type: catalytic_receptor)
Target: transforming growth factor beta receptor 2

Ligand: compound 15b [PMID: 16539403] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.449999809265137 pIC50
Reference (Journal): Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
Published in: J Med Chem

Ligand: galunisertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.679999828338623 pIC50
Reference (Journal): Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.
Published in: Oncotarget

Ligand: H. polygyrus TGF-β mimic (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.53000020980835 pKd
Reference (Journal): A structurally distinct TGF-β mimic from an intestinal helminth parasite potently induces regulatory T cells.
Published in: Nat Commun

Ligand: LY2109761 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.519999980926514 pKi
Reference (Journal): LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Published in: Mol Cancer Ther

Ligand: compound 13d [PMID: 23639540] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.590000152587891 pIC50
Reference (Journal): Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.
Published in: Bioorg Med Chem Lett

Ligand: TGFβ3 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.53000020980835 pKd
Reference (Journal): A structurally distinct TGF-β mimic from an intestinal helminth parasite potently induces regulatory T cells.
Published in: Nat Commun
Target family: Type II receptor serine/threonine kinases (type: catalytic_receptor)
Target: activin A receptor type 2A

Ligand: bimagrumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.359999656677246 pKd
Reference (Patent): Compositions and methods for increasing muscle growth.
Target family: Type II receptor serine/threonine kinases (type: catalytic_receptor)
Target: activin A receptor type 2B

Ligand: bimagrumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 11.760000228881836 pKd
Reference (Patent): Compositions and methods for increasing muscle growth.
Target family: Type II receptor serine/threonine kinases (type: catalytic_receptor)
Target: bone morphogenetic protein receptor type 2

Ligand: compound 13a [PMID: 23639540] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pIC50
Reference (Journal): Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.
Published in: Bioorg Med Chem Lett

Ligand: deucravacitinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2022), EMA (2023)
Primary target: no
Median affinity: 6.710000038146973 pIC50
Reference (Journal): Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
Published in: J Med Chem
Target family: Type II receptor serine/threonine kinases (type: catalytic_receptor)
Target: transforming growth factor beta receptor 2

Ligand: compound 13a [PMID: 23639540] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.859999656677246 pIC50
Reference (Journal): Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.
Published in: Bioorg Med Chem Lett
Target family: Type II RTKs: Insulin receptor family (type: catalytic_receptor)
Target: Insulin receptor-related receptor

Ligand: linsitinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.119999885559082 pIC50
Reference (Journal): Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.
Published in: Future Med Chem